AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6418074
Drug: Chemo-endocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemo-endocrine therapy (TAM+) in curatively resected cases
Trial: 6418074
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (TAM-) in curatively resected cases
Trial: 30693573
Drug: AL-335 800
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-335 800 mg, odalasvir 25 mg, and simeprevir 75 mg once daily for 6 weeks
Trial: 30693573
Drug: AL-335 800
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL-335 800 mg, odalasvir 25 mg, and simeprevir 75 mg once daily for 8 weeks
Trial: 27267785
Drug: Buprenorphine/naloxone rapidly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone rapidly dissolving tablets
Trial: 31336393
Drug: Î±‐tocopherol acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Î±‐tocopherol acetate (150mg/L)
Trial: 31336393
Drug: Pinus ponderosa
RxNorm normalized name: PINUS PONDEROSA POLLEN
DrugBank: Pinus ponderosa pollen (DB10746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinus ponderosa leaves (150mg/L)
Trial: 31336393
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Pinus ponderosa leaves (70mg) and Î±‐tocopherol acetate (70mg)
Trial: 27986684
Drug: RG-TFV rectal
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG-TFV rectal gel daily
Trial: 27986684
Drug: RG-TFV rectal
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG-TFV rectal gel before and after receptive anal intercourse (RAI)
Trial: 27986684
Drug: Daily gel
RxNorm normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily gel regimen
Trial: 22654431
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg twice daily)
Trial: 19626811
Drug: Intrathecal 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 1.25 mg hyperbaric bupivacaine plus cerebrospinal fluid 0.75 ml
Trial: 19626811
Drug: Propofol 1‐1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1‐1.5 mg/kg IV bolus dose and 6‐10 mg/kg/hr infusion
Trial: 17366527
Drug: Once-daily ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily ceftriaxone plus amikacin (C + A)
Trial: 17366527
Drug: Imipenem monotherapy
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem monotherapy (control)
Trial: 9442542
Drug: Scavenging at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scavenging at 45 L/min evacuation rate
Trial: 3067809
Drug: Fencamfamine 25
RxNorm normalized name: Fencamfamin
DrugBank: Fencamfamin (DB01463)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fencamfamine 25 mg
Trial: 3067809
Drug: Fencamfamine 50
RxNorm normalized name: Fencamfamin
DrugBank: Fencamfamin (DB01463)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fencamfamine 50 mg
Trial: 24351501
Drug: Antidepressants (adequate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (adequate dose for at least 6 weeks)
Trial: 18443395
Drug: Aqueous nasal
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous nasal spray 100 microg twice daily
Trial: 18443395
Drug: Nasal drop
RxNorm normalized name: Nasal Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal drop preparation 400 microg once daily
Trial: 18443395
Drug: Nasal drop
RxNorm normalized name: Nasal Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal drop preparation 400 microg twice daily
Trial: 10913928
Drug: Cyclical hPTH(1-34)
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical hPTH(1-34) therapy (50 microg/day for 28 days in 3-month cycles)
Trial: 1417010
Drug: Tegafur suppository
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tegafur suppository preoperatively + tegafur oral preparation postoperatively
Trial: 1417010
Drug: Tegafur suppository
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tegafur suppository preoperatively + UFT oral preparation postoperatively
Trial: 1417010
Drug: Tegafur oral
RxNorm normalized name: tegafur Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegafur oral preparation postoperatively
Trial: 1417010
Drug: Preoperative tegafur
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Preoperative tegafur administration
Trial: 1417010
Drug: Dukes B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dukes B patients with preoperative tegafur administration
Trial: 3893024
Drug: 1% Butoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Butoconazole nitrate (BN) vaginal cream
Trial: 3893024
Drug: 2% Butoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Butoconazole nitrate (BN) vaginal cream
Trial: 3893024
Drug: 2% Miconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Miconazole nitrate (MN) vaginal cream
Trial: 31272493
Drug: Inhaled methoxyflurane
RxNorm normalized name: methoxyflurane Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methoxyflurane (maximum dose of 2 × 3 ml)
Trial: 31272493
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo (maximum dose 2 × 5 ml)
Trial: 26329381
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram (CIT) 20 mg/day for 35 days with anodal tDCS
Trial: 26329381
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram (CIT) 20 mg/day for 35 days with cathodal tDCS
Trial: 26329381
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citalopram (CIT) with dextromethorphan (150 mg) and anodal/cathodal tDCS
Trial: 26329381
Drug: Placebo (PLC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLC) medication with anodal or cathodal tDCS
Trial: 24629063
Drug: 12-week exercise
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week exercise intervention with four group sessions and home exercises three times a week, with weekly telephone follow-up during eight weeks without group sessions.
Trial: 20605552
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy and light massage control
Trial: 7608436
Drug: Heparin (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5,000 IU) before thrombolytic treatment with saruplase (20 mg bolus + 60 mg infusion over 60 min)
Trial: 7608436
Drug: Placebo before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before thrombolytic treatment with saruplase (20 mg bolus + 60 mg infusion over 60 min)
Trial: 7608436
Drug: Heparin (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5,000 IU) before thrombolytic treatment with saruplase
Trial: 7608436
Drug: Placebo before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before thrombolytic treatment with saruplase
Trial: 2789272
Drug: High‐dose leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose leucovorin plus 5‐FU (arm B)
Trial: 2789272
Drug: Sequential methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential methotrexate, 5‐FU, and leucovorin (arm C)
Trial: 342557
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (6 sessions of verbal self-instructions via modeling with response-cost contingent upon errors)
Trial: 342557
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (similar training without specific treatment)
Trial: 30711698
Drug: 2-dose HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose HPV vaccine
Trial: 30711698
Drug: 3-dose HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose HPV vaccine
Trial: 23899172
Drug: Genistein (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genistein (54 mg/day) for 6 months
Trial: 19958521
Drug: Anatibant (low,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatibant (low, medium, or high dose)
Trial: 19958521
Drug: Anatibant (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anatibant (any dose)
Trial: 16430668
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion strategy (trigger at 8 g/dl)
Trial: 16430668
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (trigger at 10 g/dl)
Trial: 15582838
Drug: Oxcarbazepine (OXC)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OXC) - 1200 mg
Trial: 15582838
Drug: Phenytoin (PHT)
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin (PHT) - 360 mg
Trial: 10651210
Drug: Cibenzoline 25
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline 25 mg/day
Trial: 10651210
Drug: Cibenzoline 50
RxNorm normalized name: cibenzoline
DrugBank: Cibenzoline (DB13358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline 50 mg/day
Trial: 10651210
Drug: Cibenzoline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cibenzoline (25 and 50 mg/day)
Trial: 8450580
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 g polyglucose, Polycose)
Trial: 2945499
Drug: Chlorpheniramine maleate
RxNorm normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine maleate (CTM) 12 mg
Trial: 2945499
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of loratadine
Trial: 3041936
Drug: Carteolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol (2.5 to 5.0 mg/d for an average of 328 days)
Trial: 30760406
Drug: TKIs treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKIs treatment (first-line)
Trial: 28697773
Drug: Electroacupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture treatment for 5 days
Trial: 25040321
Drug: Propofol injected
RxNorm normalized name: propofol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4.
Trial: 12766621
Drug: 1.32 ml
RxNorm normalized name: 1.32 ML Invega 311 MG/ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.32 ml of 95% alcohol per kilogram of body weight, mixed with orange juice
Trial: 3514368
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of PGE2 in 2.5 ml of Triacetin gel
Trial: 3514368
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PGE2 gel with conventional oxytocin induction
Trial: 27645244
Drug: Narlaprevir (NVR)
RxNorm normalized name: Paritaprevir
DrugBank: Narlaprevir (DB14760)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Narlaprevir (NVR) 200 mg
Trial: 27645244
Drug: Narlaprevir (NVR)
RxNorm normalized name: Paritaprevir
DrugBank: Narlaprevir (DB14760)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Narlaprevir (NVR) 100 mg with Ritonavir (RTV) 100 mg
Trial: 25170231
Drug: Tandospirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone (10 mg thrice daily) and pinaverium (50 mg thrice daily)
Trial: 25170231
Drug: Pinaverium (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium (50 mg thrice daily) and placebo
Trial: 12357161
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g acetaminophen
Trial: 12357161
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g acetaminophen and 50 mg rofecoxib
Trial: 12357161
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg vitamin C (placebo)
Trial: 10204818
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (60 mg twice daily) for 8 weeks
Trial: 2182300
Drug: Intravenous ketanserin
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketanserin
Trial: 6446424
Drug: Intra-amniotic injection
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic injection of dehydroepiandrosterone sulphate (DHEA-S) (100-200 mg)
Trial: 6446424
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of dehydroepiandrosterone sulphate (DHEA-S) (100 mg)
Trial: 29091327
Drug: Peg‐IFN‐α‐2a add‐on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peg‐IFN‐α‐2a add‐on therapy
Trial: 16135583
Drug: Intrauterine 5‐mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine 5‐mL 2% lidocaine
Trial: 12042267
Drug: 150 microg
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg desogestrel p.o. daily for 24 weeks with 400 mg testosterone pellets s.c. on day 1 and at 12 weeks
Trial: 12042267
Drug: 300 microg
RxNorm normalized name: Voglibose 300 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 microg desogestrel p.o. daily for 24 weeks with 400 mg testosterone pellets s.c. on day 1 and at 12 weeks
Trial: 9543120
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment (0.3 mg/kg x week, mean duration = 41 months)
Trial: 8304654
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral acyclovir (800 mg four times daily)
Trial: 8304654
Drug: Preemptive, short-course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive, short-course ganciclovir therapy (5 mg/kg intravenously twice daily for 7 days if CMV shedding occurred)
Trial: 2729815
Drug: lyophilized collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lyophilized collagen pads as adjunctive treatment
Trial: 29247643
Drug: LFS‐01 (sulforaphene)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFS‐01 (sulforaphene) treatment
Trial: 23073723
Drug: Buspirone 10
RxNorm normalized name: busPIRone 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 10 mg/day
Trial: 21282192
Drug: DDMM (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDMM (2 doses of DNA followed by 2 doses of rMVA)
Trial: 21282192
Drug: DMM (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMM (1 dose of DNA followed by 2 doses of rMVA)
Trial: 21282192
Drug: MMM (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMM (3 doses of rMVA)
Trial: 21282192
Drug: 1/10th-dose DDMM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/10th-dose DDMM regimen
Trial: 15080848
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously once daily for up to 42 days
Trial: 9312206
Drug: Intramuscular SCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular SCT (IM)
Trial: 7865076
Drug: NaF dentifrices
RxNorm normalized name: DENTIFRICES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaF dentifrices (1000 or 1500 micrograms F/g)
Trial: 7865076
Drug: Na2FPO3 dentifrices
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Na2FPO3 dentifrices (1000 or 1500 micrograms F/g)
Trial: 2511277
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms of recombinant IFN-gamma given once weekly
Trial: 240112
Drug: Beta adrenergic
RxNorm normalized name: Beta adrenergic receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta adrenergic blocking agents
Trial: 240112
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of beta adrenergic blocking agents with peripheral vasodilators (e.g., hydrallazine, prazosin)
Trial: 31513552
Drug: Community empowerment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community empowerment model of combination HIV prevention (Project Shikamana)
Trial: 20079922
Drug: 0.59-mg FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.59-mg FA intravitreal implant
Trial: 15983798
Drug: Modafinil 200
RxNorm normalized name: modafinil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil 200 mg + Clonidine 0.2 mg
Trial: 10659924
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (estradiol 50 microg/day) combined with oral medroxyprogesterone acetate (MPA) 10 mg/day for 12 days/month
Trial: 10659924
Drug: Tibolone tablets
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone tablets 2.5 mg/day
Trial: 31393444
Drug: Intramuscular Retinalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Retinalamin injections
Trial: 26105520
Drug: Pomegranate extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate extract (PE) 900 mg daily before surgery
Trial: 23182608
Drug: Remifentanil 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.50 μg/kg
Trial: 23182608
Drug: Remifentanil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.0 μg/kg
Trial: 23182608
Drug: Remifentanil 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.25 μg/kg
Trial: 16639483
Drug: Bone sparing
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone sparing agents (hormone therapy, bisphosphonates, PTH 1‐34)
Trial: 9261583
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis with cefazolin
Trial: 8337215
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate infusion during panic attack
Trial: 3013442
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (M) with VAC (vincristine, doxorubicin, and cyclophosphamide) at a lower dosage, given every 4 weeks for 8 courses.
Trial: 3013442
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance chemotherapy (NM), no further treatment until relapse.
Trial: 26376111
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg PD‐0360324
Trial: 26376111
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg PD‐0360324
Trial: 26376111
Drug: PD‐0360324 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD‐0360324 (both doses)
Trial: 20455761
Drug: Nonnucleoside reverse
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonnucleoside reverse transcriptase inhibitors (NNRTIs) - nevirapine (NVP) and efavirenz (EFV)
Trial: 15749485
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) 50 mg on days 5-9
Trial: 11025237
Drug: Subarachnoid injection
RxNorm normalized name: TETRACAINE HYDROCHLORIDE 10 mg in 1 mL SUBARACHNOID INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid injection of 12 mg hyperbaric bupivacaine
Trial: 6666218
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (40 mg orally every 6 h for 3 months)